Abstract:Hormone therapy targeting estrogen receptors is widely used clinically for the treatment of breast cancer, such as tamoxifen, but most of them are partial agonists, which can cause serious side effects after long-term use. The use of selective estrogen receptor down-regulators (SERDs) may be an effective alternative to breast cancer therapy by directly degrading ERα protein to shut down ERα signaling. However, the solely clinically used SERD fulvestrant, is low orally bioavailable and requires intravenous injection, which severely limits its clinical application. On the other hand, double- or multi-target conjugates, which are able to synergize antitumor activity by different pathways, thus may enhance therapeutic effect in comparison with single targeted therapy. In this study, we designed and synthesized a series of novel dual-functional conjugates targeting both ERα degradation and histone deacetylase inhibiton by combining a privileged SERD skeleton 7-oxabicyclo[2.2.1]heptane sulfonamide (OBHSA) with a histone deacetylase inhibitor side chain. We found that substituents on both the sulfonamide nitrogen and phenyl group of OBHSA unit had significant effect on biological activities. Among them, conjugate 16i with N-methyl and naphthyl groups exhibited potent antiproliferative activity against MCF-7 cells, and excellent ERα degradation activity and HDACs inhibitory ability. A further molecular docking study indicated the interaction patterns of these conjugates with ERα, which may provide guidance to design novel SERDs or PROTAC-like SERDs for breast cancer therapy.

Synthesis and Structure–activity Relationships of Novel Hybrid Ferrocenyl Compounds Based on a Bicyclic Core Skeleton for Breast Cancer Therapy

Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.

Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy

Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells.

Design, Synthesis and Biological Evaluation of Novel Dual-Acting Modulators Targeting Both Estrogen Receptor Α (erα) and Lysine-Specific Demethylase 1 (LSD1) for Treatment of Breast Cancer.

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Development of Novel Tetrahydroisoquinoline-Hydroxamate Conjugates As Potent Dual SERDs/HDAC Inhibitors for the Treatment of Breast Cancer

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Structural Optimization of Tetrahydroisoquinoline-Hydroxamate Hybrids As Potent Dual ERα Degraders and HDAC Inhibitors.

Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.

Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency Against Breast Cancer

Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: an Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators Against Endocrine-Resistant Breast Cancer.

Diversity-oriented synthesis and bioactivity evaluation of N-substituted ferrocifen compounds as novel antiproliferative agents against TNBC cancer cells

Rational Design and Optimization of Selenophenes with Basic Side Chains As Novel Potent Selective Estrogen Receptor Modulators (serms) for Breast Cancer Therapy.

New ferrocene cyclopalladated compounds: synthesis, X-ray single crystal structure and in vitro anticancer activity study

Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities Against Tumor Growth and Metastasis

3-Acyl-5-hydroxybenzofuran derivatives as potential anti-estrogen breast cancer agents: A combined experimental and theoretical investigation

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Discovery of Novel Steroidal-Chalcone Hybrids with Potent and Selective Activity Against Triple-Negative Breast Cancer.

X-ray Crystallography Study and Optimization of Novel Benzothiophene Analogs As Potent Selective Estrogen Receptor Covalent Antagonists (sercas) with Improved Potency and Safety Profiles.

Synthesis and Antiproliferative Evaluation of Novel Hydroxypropyl-Ferrociphenol Derivatives, Resulting from the Modification of Hydroxyl Groups